Establishment Labs Raises Full-Year Guidance on Strong Q2 Growth
Event summary
- Q2 revenue up 31.7% YoY to $67.5M, with U.S. sales growing 26% QoQ to $24.7M.
- Adjusted EBITDA turned positive at $3.7M, vs. a loss of $8.5M in Q2 2025.
- Full-year revenue guidance raised from $266.5M–$268.5M to $269M–$271M.
- Cash balance improved by $3.1M QoQ to $71.2M as of June 30, 2026.
The big picture
Establishment Labs is capitalizing on demand for minimally invasive breast aesthetics and reconstruction solutions, a segment benefiting from post-pandemic procedural recovery. The company’s ability to raise guidance reflects its success in capturing market share through product innovation and geographic expansion. With $71.2M in cash reserves and improving profitability, Establishment Labs appears positioned to invest further in R&D and commercialization.
What we're watching
- Market Share Dynamics
- Whether Establishment Labs can sustain its accelerating adoption of minimally invasive platforms in the U.S. and globally.
- Profitability Trends
- The pace at which gross margins (70.6% in Q2) will expand as higher-margin U.S. business scales.
- Cash Flow Inflection
- How quickly the company achieves free cash flow positivity amid rising revenue and improving operational leverage.
Related topics